A New Dawn: At The Cusp Of The CNS Decade

After nearly two decades of sluggish growth and many R&D disappointments, the stars are aligning for a new wave of breakthrough innovations for the treatment of central nervous system (CNS) disorders. Unprecedented scientific progress is leading to a deeper understanding of the underlying, complex biology of these conditions, unlocking new drug targets and novel modes of action. At the same time, disruptive digital technologies are transforming R&D approaches and create new possibilities for diagnosing, treating and supporting CNS patients throughout their disease journey.

For the purpose of this white paper, the term CNS disorders encompasses mental illnesses and non-communicable, neurological conditions.¹ This research explores the enablers of R&D breakthroughs in the treatment of these conditions, examines trends in how the pharmaceutical industry is embracing this momentous opportunity and identifies critical success factors for CNS innovators.